Entyvio 300 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FQQA6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $99,325
Award facts
- Contract value 100% obligated
- $99,325.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $99,325 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Entyvio 300 mg vials. The award, issued on January 8, 2026, with an ultimate completion date of January 9, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion acquisition strategy designed to establish regional prime vendor contractors supplying pharmaceutical products to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with substantial contracting activity through the Defense Logistics Agency's Medical Supply Chain division. The company's product portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, positioning it to fulfill the diverse and specialized pharmaceutical requirements of military healthcare operations. The delivery order for Entyvio—a biologic immunosuppressant medication—reflects the contractor's capability to supply specialized therapeutic products essential to DOD medical operations, with performance on previous delivery orders demonstrating consistent contract execution across multiple product categories.
Quick answers
Who was awarded contract SPE2DR26FQQA6?
SPE2DR26FQQA6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 8, 2026.
How much is contract SPE2DR26FQQA6 worth?
The government has obligated $99,325 on SPE2DR26FQQA6.
Is contract SPE2DR26FQQA6 an order under another contract?
Yes. SPE2DR26FQQA6 is a delivery order under SPE2DR25D9331, an indefinite delivery contract.
Was contract SPE2DR26FQQA6 competed?
The extent of competition for SPE2DR26FQQA6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award